Clinical trial
A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Single Dose Regimen Study of LMN-101 in Healthy Volunteers Challenged With Campylobacter Jejuni
NCT04182490 is registered in ClinicalTrials.gov with Lumen Bioscience, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Single Dose Regimen Study of LMN-101 in Healthy Volunteers Challenged With Campylobacter Jejuni
- Lead sponsor
- Lumen Bioscience, Inc.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- February 21, 2022
- Completion date
- October 4, 2022
- Enrollment
- 42 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.